A FAAH-fetched approach to treat osteoarthritis pain

Pain

Volumn 152, Issue 5, 2011, Pages 959-960

  Lichtman, Aron H ^a   Chapman, Victoria ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CANNABINOID; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DRONABINOL; PF 0445784; PF 04457845; UNCLASSIFIED DRUG;

ANALGESIA; DRUG MECHANISM; NOCICEPTION; NONHUMAN; NOTE; OSTEOARTHRITIS; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT RESPONSE;

EID: 79954606127     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2011.02.034     Document Type: Editorial

References (20)

1. K. Ahn, D.S. Johnson, and B.F. Cravatt Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders Expert Opin Drug Discov 4 2009 763 784
2. K. Ahn, M.K. McKinney, and B.F. Cravatt Enzymatic pathways that regulate endocannabinoid signaling in the nervous system Chem Rev 108 2008 1687 1707 (Pubitemid 351796405)
3. B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, and N.B. Gilula Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides Nature 384 1996 83 87 (Pubitemid 26374593)
4. G. Gobbi, F.R. Bambico, R. Mangieri, M. Bortolato, P. Campolongo, M. Solinas, T. Cassano, M.G. Morgese, G. Debonnel, A. Duranti, A. Tontini, G. Tarzia, M. Mor, V. Trezza, S.R. Goldberg, V. Cuomo, and D. Piomelli Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis Proc Natl Acad Sci USA 102 2005 18620 18625 (Pubitemid 43011275)
5. S. Kathuria, S. Gaetani, D. Fegley, F. Valino, A. Duranti, A. Tontini, M. Mor, G. Tarzia, G.L. Rana, A. Calignano, A. Giustino, M. Tattoli, M. Palmery, V. Cuomo, and D. Piomelli Modulation of anxiety through blockade of anandamide hydrolysis Nat Med 9 2003 76 81 (Pubitemid 36098263)
6. A.H. Lichtman, D. Leung, C. Shelton, A. Saghatelian, C. Hardouin, D. Boger, and B.F. Cravatt Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity J Pharmacol Exp Ther 311 2004 441 448 (Pubitemid 39391527)
7. R. Noyes Jr., S.F. Brunk, D.A. Avery, and A.C. Canter The analgesic properties of delta-9-tetrahydrocannabinol and codeine Clin Pharmacol Ther 18 1975 84 89
8. R. Noyes Jr., S.F. Brunk, D.A. Baram, and A. Canter Analgesic effect of delta-9-tetrahydrocannabinol J Clin Pharmacol 15 1975 139 143
9. Pfizer. A Phase 2a randomized, double-blinded, double dummy, placebo and active controlled, two-way cross-over, flare-enriched multi-centre clinical trial to examine the pain relief produced by 2 weeks of daily oral administration of a fatty acid amide hydrolase (FAAH) inhibitor PF-04457845 in patients with osteoarthritis of the knee, 2010. Available at: http://clinicaltrials.gov/ct2/results?term=NCT00981357 ; access date 2/13/11.
10. R. Poole, S. Blake, M. Buschmann, S. Goldring, S. Laverty, S. Lockwood, J. Matyas, J. McDougall, K. Pritzker, K. Rudolphi, W. van den Berg, and T. Yaksh Recommendations for the use of preclinical models in the study and treatment of osteoarthritis Osteoarthritis Cartilage 18 2010 S10 S16
11. D. Raft, J. Gregg, J. Ghia, and L. Harris Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response Clin Pharmacol Ther 21 1977 26 33 (Pubitemid 8024156)
12. D. Richardson, R.G. Pearson, N. Kurian, M.L. Latif, M.J. Garle, D.A. Barrett, D.A. Kendall, B.E. Scammell, A.J. Reeve, and V. Chapman Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis Arthritis Res Ther 10 2008 R43
13. D.R. Sagar, L.E. Staniaszek, B.N. Okine, S. Woodhams, L.M. Norris, R.G. Pearson, M.J. Garle, S.P. Alexander, A.J. Bennett, D.A. Barrett, D.A. Kendall, B.E. Scammell, and V. Chapman Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor system in a rat model of osteoarthritis pain Arthritis Rheum 62 2010 3666 3676
14. J.E. Schlosburg, S.G. Kinsey, and A.H. Lichtman Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation AAPS J 11 2009 39 44
15. N. Schuelert, M.P. Johnson, J.L. Oskins, K. Jassal, M.G. Chambers, and J.J. McDougall Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis Pain 152 2011 975 981
16. M.A. Ware, C.R. Doyle, R. Woods, M.E. Lynch, and A.J. Clark Cannabis use for chronic non-cancer pain: results of a prospective survey Pain 102 2003 211 216 (Pubitemid 36298878)
17. M.A. Ware, T. Ducruet, and A.R. Robinson Evaluation of herbal cannabis characteristics by medical users: a randomized trial Harm Reduct J 3 2006 32
18. M.A. Ware, M.A. Fitzcharles, L. Joseph, and Y. Shir The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial Anesth Analg 110 2010 604 610
19. M.A. Ware, T. Wang, S. Shapiro, A. Robinson, T. Ducruet, T. Huynh, A. Gamsa, G.J. Bennett, and J.P. Collet Smoked cannabis for chronic neuropathic pain: a randomized controlled trial Can Med Assoc J 182 2010 E694 E701
20. S. Wright, M. Ware, and G. Guy The use of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis Rheumatology (Oxford) 45 2006 781 (author reply 781-2) (Pubitemid 43985356)